Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Vecabrutinib for B-lymphoid malignancies

Susan O’Brien • 1 Dec 2018
ASH 2018
Leukemia Vecabrutinib

Ibrutinib, a BTK inhibitor, is an excellent option for the treatment of B-lymphoid cancers; however, patients eventually become refractory due to the development of resistance. Here, Susan O’Brien, MD, of the University of California, Irvine, CA, provides an overview of the use of vecabrutinib, a next-generation competitive BTK inhibitor, which should prevent the acquisition of resistance. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. O’Brien highlights the Phase I dose escalation study (NCT03037645) evaluating the clinical activity, safety and pharmacodynamics of this treatment.

More from Susan O’Brien

2:03
Venetoclax and obinutuzumab combination therapy for CLL
Susan O’Brien • 14 Jun 2019
2:19
CAR T-cell therapy updates in CLL
Susan O’Brien • 14 Jun 2019
2:00
CLL RESONATE-2: Five-year follow-up
Susan O’Brien • 13 Jun 2019
3:19
Zanubrutinib and acalabrutinib for CLL: potential alternatives to ibrutinib?
Susan O’Brien • 15 Jun 2019

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals